Cytomics and drug discovery.
Pharmaceutical companies try to develop new drugs that have a high success rate of reaching the market. However, current disease models lack a strong correlation to clinical reality, because of the underestimation of the complexity and variability of clinical disease processes. This leads to high attrition rates late in drug development and soaring costs. Improvement of disease models is an important issue to reduce the high attrition rates in drug development. Using cell-based disease models, which should take into account the molecular diversity of the human cytome, will improve the predictive value of drug discovery.
Maia Scientific N.V., Geel, Belgium. pvosta@maia-scientific.com
Peter
P
Van Osta
Kris
K
Ver Donck
Luc
L
Bols
Johan
J
Geysen
D035843:Biomedical Research / Q000379:methods*; D003585:Cell Biology / Q000639:trends*; D015195:Drug Design; D004345:Drug Industry / Q000191:economics / Q000379:methods*; D005057:Eukaryotic Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D005434:Flow Cytometry / Q000639:trends; D015894:Genome, Human / Q000235:genetics; D006801:Humans; D019044:Image Cytometry / Q000639:trends